A combination of TRAIL (a tumor necrosis factor) and sorafenib (an inhibitor currently used to treat renal cancer) has been found to reduce the size of tumors in mice with colon carcinomas with few side effects – thereby demonstrating the potential effectiveness of the combined treatment on human colon cancers.
Such were the new combination therapy [...]